Krogsgaard: The alternative would be a major acquisition
Novo Nordisk CSO Mads Krogsgaard Thomsen admits that it has been more difficult than expected to deliver within the now abandoned inflammation unit. The company’s four attempts all missed the target and the alternative to abandoning the entire project would have been a major acquisition.
It was quite a gamble when Novo Nordisk entered the scene for inflammatory diseases, and a gamble that failed. That is why the Danish drug group recently decided to cash in its chips and close down the unit, chief scientific officer Mads Krogsgaard Thomsen tells MedWatch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo to hire 6,000 in Denmark
For abonnenter
